Maya Ando
Juntendo University
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Maya Ando.
Lancet Neurology | 2015
Manabu Funayama; Kenji Ohe; Taku Amo; Norihiko Furuya; Junji Yamaguchi; Shinji Saiki; Yuanzhe Li; Kotaro Ogaki; Maya Ando; Hiroyo Yoshino; Hiroyuki Tomiyama; Kenya Nishioka; Kazuko Hasegawa; Hidemoto Saiki; Wataru Satake; Kaoru Mogushi; Ryogen Sasaki; Yasumasa Kokubo; Shigeki Kuzuhara; Tatsushi Toda; Yoshikuni Mizuno; Yasuo Uchiyama; Kinji Ohno; Nobutaka Hattori
BACKGROUND Identification of causative genes in mendelian forms of Parkinsons disease is valuable for understanding the cause of the disease. We did genetic studies in a Japanese family with autosomal dominant Parkinsons disease to identify novel causative genes. METHODS We did a genome-wide linkage analysis on eight affected and five unaffected individuals from a family with autosomal dominant Parkinsons disease (family A). Subsequently, we did exome sequencing on three patients and whole-genome sequencing on one patient in family A. Variants were validated by Sanger sequencing in samples from patients with autosomal dominant Parkinsons disease, patients with sporadic Parkinsons disease, and controls. Participants were identified from the DNA bank of the Comprehensive Genetic Study on Parkinsons Disease and Related Disorders (Juntendo University School of Medicine, Tokyo, Japan) and were classified according to clinical information obtained by neurologists. Splicing abnormalities of CHCHD2 mutants were analysed in SH-SY5Y cells. We used the Fishers exact test to calculate the significance of allele frequencies between patients with sporadic Parkinsons disease and unaffected controls, and we calculated odds ratios and 95% CIs of minor alleles. FINDINGS We identified a missense mutation (CHCHD2, 182C>T, Thr61Ile) in family A by next-generation sequencing. We obtained samples from a further 340 index patients with autosomal dominant Parkinsons disease, 517 patients with sporadic Parkinsons disease, and 559 controls. Three CHCHD2 mutations in four of 341 index cases from independent families with autosomal dominant Parkinsons disease were detected by CHCHD2 mutation screening: 182C>T (Thr61Ile), 434G>A (Arg145Gln), and 300+5G>A. Two single nucleotide variants (-9T>G and 5C>T) in CHCHD2 were confirmed to have different frequencies between sporadic Parkinsons disease and controls, with odds ratios of 2·51 (95% CI 1·48-4·24; p=0·0004) and 4·69 (1·59-13·83, p=0·0025), respectively. One single nucleotide polymorphism (rs816411) was found in CHCHD2 from a previously reported genome-wide association study; however, there was no significant difference in its frequency between patients with Parkinsons disease and controls in a previously reported genome-wide association study (odds ratio 1·17, 95% CI 0·96-1·19; p=0·22). In SH-SY5Y cells, the 300+5G>A mutation but not the other two mutations caused exon 2 skipping. INTERPRETATION CHCHD2 mutations are associated with, and might be a cause of, autosomal dominant Parkinsons disease. Further genetic studies in other populations are needed to confirm the pathogenicity of CHCHD2 mutations in autosomal dominant Parkinsons disease and susceptibility for sporadic Parkinsons disease, and further functional studies are needed to understand how mutant CHCHD2 might play a part in the pathophysiology of Parkinsons disease. FUNDING Japan Society for the Promotion of Science; Japanese Ministry of Education, Culture, Sports, Science and Technology; Japanese Ministry of Health, Labour and Welfare; Takeda Scientific Foundation; Cell Science Research Foundation; and Nakajima Foundation.
Movement Disorders | 2012
Maya Ando; Manabu Funayama; Yuanzhe Li; Kenichi Kashihara; Yoshitake Murakami; Nobutaka Ishizu; Chizuko Toyoda; Katsuhiko Noguchi; Takashi Hashimoto; Naoki Nakano; Ryogen Sasaki; Yasumasa Kokubo; Shigeki Kuzuhara; Kotaro Ogaki; Chikara Yamashita; Hiroyo Yoshino; Taku Hatano; Hiroyuki Tomiyama; Nobutaka Hattori
Vacuolar protein sorting 35 (VPS35) was recently reported to be a pathogenic gene for late‐onset autosomal dominant Parkinsons disease (PD), using exome sequencing. To date, VPS35 mutations have been detected only in whites with PD. The aim of the present study was to determine the incidence and clinical features of Asian PD patients with VPS35 mutations. We screened 7 reported nonsynonymous missense variants of VPS35, including p.D620N, known as potentially disease‐associated variants of PD, in 300 Japanese index patients with autosomal dominant PD and 433 patients with sporadic PD (SPD) by direct sequencing or high‐resolution melting (HRM) analysis. In addition, we screened 579 controls for the p.D620N mutation by HRM analysis. The p.D620N mutation was detected in 3 patients with autosomal dominant PD (1.0%), in 1 patient with SPD (0.23%), and in no controls. None of the other reported variants of VPS35 were detected. Haplotype analysis suggested at least 3 independent founders for Japanese patients with p.D620N mutation. Patients with the VPS35 mutation showed typical tremor‐predominant PD. We report Asian PD patients with the VPS35 mutation. Although VPS35 mutations are uncommon in PD, the frequency of such mutation is relatively higher in Japanese than reported in other populations. In VPS35, p.D620N substitution may be a mutational hot spot across different ethnic populations. Based on the clinical features, VPS35 should be analyzed in patients with PD, especially autosomal dominant PD or tremor‐predominant PD.
EMBO Reports | 2015
Fabienne C. Fiesel; Maya Ando; Roman Hudec; Anneliese R Hill; Monica Castanedes-Casey; Thomas R. Caulfield; Elisabeth L. Moussaud-Lamodière; Jeannette N. Stankowski; Peter O. Bauer; Oswaldo Lorenzo-Betancor; Isidre Ferrer; José Matías Arbelo; Joanna Siuda; Li Chen; Valina L. Dawson; Ted M. Dawson; Zbigniew K. Wszolek; Owen A. Ross; Dennis W. Dickson; Wolfdieter Springer
Mutations in PINK1 and PARKIN cause recessive, early‐onset Parkinsons disease (PD). Together, these two proteins orchestrate a protective mitophagic response that ensures the safe disposal of damaged mitochondria. The kinase PINK1 phosphorylates ubiquitin (Ub) at the conserved residue S65, in addition to modifying the E3 ubiquitin ligase Parkin. The structural and functional consequences of Ub phosphorylation (pS65‐Ub) have already been suggested from in vitro experiments, but its (patho‐)physiological significance remains unknown. We have generated novel antibodies and assessed pS65‐Ub signals in vitro and in cells, including primary neurons, under endogenous conditions. pS65‐Ub is dependent on PINK1 kinase activity as confirmed in patient fibroblasts and postmortem brain samples harboring pathogenic mutations. We show that pS65‐Ub is reversible and barely detectable under basal conditions, but rapidly induced upon mitochondrial stress in cells and amplified in the presence of functional Parkin. pS65‐Ub accumulates in human brain during aging and disease in the form of cytoplasmic granules that partially overlap with mitochondrial, lysosomal, and total Ub markers. Additional studies are now warranted to further elucidate pS65‐Ub functions and fully explore its potential for biomarker or therapeutic development.
Journal of Cell Science | 2014
Fabienne C. Fiesel; Elisabeth L. Moussaud-Lamodière; Maya Ando; Wolfdieter Springer
ABSTRACT Loss-of-function mutations in the genes encoding PINK1 and Parkin (also known as PARK2) are the most common causes of recessive Parkinsons disease. Both together mediate the selective degradation of mitochondrial proteins and whole organelles via the proteasome and the autophagy-lysosome pathway (mitophagy). The mitochondrial kinase PINK1 activates and recruits the E3 ubiquitin ligase Parkin to de-energized mitochondria. However, the cognate E2 co-enzymes of Parkin in this ubiquitin-dependent pathway have not been investigated. Here, we discovered a total of four E2s that either positively or negatively regulate the activation, translocation and enzymatic functions of Parkin during mitochondrial quality control. UBE2D family members and UBE2L3 redundantly charged the RING-HECT hybrid ligase Parkin with ubiquitin, resulting in its initial activation and translocation to mitochondria. UBE2N, however, primarily operated through a different mechanism in order to mediate the proper clustering of mitochondria, a prerequisite for degradation. Strikingly, in contrast to UBE2D, UBE2L3 and UBE2N, depletion of UBE2R1 resulted in enhanced Parkin translocation and clustering upon mitochondrial uncoupling. Our study uncovered redundant, cooperative or antagonistic functions of distinct E2 enzymes in the regulation of Parkin and mitophagy that might suggest a putative role in Parkinsons disease pathogenesis.
Brain | 2017
Andreas Puschmann; Fabienne C. Fiesel; Thomas R. Caulfield; Roman Hudec; Maya Ando; Dominika Truban; Xu Hou; Kotaro Ogaki; Michael G. Heckman; Elle D. James; Maria Swanberg; Itzia Jimenez-Ferrer; Oskar Hansson; Grzegorz Opala; Joanna Siuda; Magdalena Boczarska-Jedynak; Andrzej Friedman; Dariusz Koziorowski; Jan O. Aasly; Timothy Lynch; George D. Mellick; Megha Mohan; Peter A. Silburn; Yanosh Sanotsky; Carles Vilariño-Güell; Matthew J. Farrer; Li Chen; Valina L. Dawson; Ted M. Dawson; Zbigniew K. Wszolek
See Gandhi and Plun-Favreau (doi:10.1093/aww320) for a scientific commentary on this article. It has been postulated that heterozygous mutations in recessive Parkinson’s genes may increase the risk of developing the disease. In particular, the PTEN-induced putative kinase 1 (PINK1) p.G411S (c.1231G>A, rs45478900) mutation has been reported in families with dominant inheritance patterns of Parkinson’s disease, suggesting that it might confer a sizeable disease risk when present on only one allele. We examined families with PINK1 p.G411S and conducted a genetic association study with 2560 patients with Parkinson’s disease and 2145 control subjects. Heterozygous PINK1 p.G411S mutations markedly increased Parkinson’s disease risk (odds ratio = 2.92, P = 0.032); significance remained when supplementing with results from previous studies on 4437 additional subjects (odds ratio = 2.89, P = 0.027). We analysed primary human skin fibroblasts and induced neurons from heterozygous PINK1 p.G411S carriers compared to PINK1 p.Q456X heterozygotes and PINK1 wild-type controls under endogenous conditions. While cells from PINK1 p.Q456X heterozygotes showed reduced levels of PINK1 protein and decreased initial kinase activity upon mitochondrial damage, stress-response was largely unaffected over time, as expected for a recessive loss-of-function mutation. By contrast, PINK1 p.G411S heterozygotes showed no decrease of PINK1 protein levels but a sustained, significant reduction in kinase activity. Molecular modelling and dynamics simulations as well as multiple functional assays revealed that the p.G411S mutation interferes with ubiquitin phosphorylation by wild-type PINK1 in a heterodimeric complex. This impairs the protective functions of the PINK1/parkin-mediated mitochondrial quality control. Based on genetic and clinical evaluation as well as functional and structural characterization, we established p.G411S as a rare genetic risk factor with a relatively large effect size conferred by a partial dominant-negative function phenotype.
Neurology | 2015
Kotaro Ogaki; Shunsuke Koga; Michael G. Heckman; Fabienne C. Fiesel; Maya Ando; Catherine Labbé; Oswaldo Lorenzo-Betancor; Elisabeth L. Moussaud-Lamodière; Alexandra I. Soto-Ortolaza; Ronald L. Walton; Audrey Strongosky; Ryan J. Uitti; Allan McCarthy; Timothy Lynch; Joanna Siuda; Grzegorz Opala; Monika Rudzińska; Anna Krygowska-Wajs; Maria Barcikowska; Krzysztof Czyzewski; Andreas Puschmann; Kenya Nishioka; Manabu Funayama; Nobutaka Hattori; Joseph E. Parisi; Ronald C. Petersen; Neill R. Graff-Radford; Bradley F. Boeve; Wolfdieter Springer; Zbigniew K. Wszolek
Objective: To assess the role of CHCHD2 variants in patients with Parkinson disease (PD) and Lewy body disease (LBD) in Caucasian populations. Methods: All exons of the CHCHD2 gene were sequenced in a US Caucasian patient-control series (878 PD, 610 LBD, and 717 controls). Subsequently, exons 1 and 2 were sequenced in an Irish series (355 PD and 365 controls) and a Polish series (394 PD and 350 controls). Immunohistochemistry and immunofluorescence studies were performed on pathologic LBD cases with rare CHCHD2 variants. Results: We identified 9 rare exonic variants of unknown significance. These variants were more frequent in the combined group of PD and LBD patients compared to controls (0.6% vs 0.1%, p = 0.013). In addition, the presence of any rare variant was more common in patients with LBD (2.5% vs 1.0%, p = 0.050) compared to controls. Eight of these 9 variants were located within the genes mitochondrial targeting sequence. Conclusions: Although the role of variants of the CHCHD2 gene in PD and LBD remains to be further elucidated, the rare variants in the mitochondrial targeting sequence may be a risk factor for Lewy body disorders, which may link CHCHD2 to other genetic forms of parkinsonism with mitochondrial dysfunction.
Parkinsonism & Related Disorders | 2015
Asako Yoritaka; Sumihiro Kawajiri; Yorihiro Yamamoto; Toshiki Nakahara; Maya Ando; Kazuhiko Hashimoto; Midori Nagase; Yufuko Saito; Nobutaka Hattori
INTRODUCTION Mitochondrial complex I deficiencies have been found in post-mortem brains of patients with Parkinsons disease (PD). Coenzyme Q10 (CoQ10) is the electron acceptor found in complexes I and II, and is a potent antioxidant. A recent trial of the oxidized form of CoQ10 for PD failed to show benefits; however, the reduced form of CoQ10 (ubiquinol-10) has shown better neuroprotective effects in animal models. METHODS Randomized, double-blind, placebo-controlled, parallel-group pilot trials were conducted to assess the efficacy of ubiquinol-10 in Japanese patients with PD. Participants were divided into two groups: PD experiencing wearing off (Group A), and early PD, without levodopa (with or without a dopamine agonist) (Group B). Participants took 300 mg of ubiquinol-10 or placebo per day for 48 weeks (Group A) or 96 weeks (Group B). RESULTS In Group A, total Unified Parkinsons Disease Rating Scale (UPDRS) scores decreased in the ubiquinol-10 group (n = 14; mean ± SD [-4.2 ± 8.2]), indicating improvement in symptoms. There was a statistically significant difference (p < 0.05) compared with the placebo group (n = 12; 2.9 ± 8.9). In Group B, UPDRS increased in the ubiquinol-10 group (n = 14; 3.9 ± 8.0), as well as in the placebo group (n = 8; 5.1 ± 10.3). CONCLUSIONS This is the first report showing that ubiquinol-10 may significantly improve PD with wearing off, as judged by total UPDRS scores, and that ubiquinol-10 is safe and well tolerated.
Neurobiology of Aging | 2014
Chikara Yamashita; Hiroyuki Tomiyama; Manabu Funayama; Saeko Inamizu; Maya Ando; Yuanzhe Li; Hiroyo Yoshino; Takehisa Araki; Tadashi Ichikawa; Yoshiro Ehara; Kinya Ishikawa; Hidehiro Mizusawa; Nobutaka Hattori
We evaluated the contributions of various polyglutamine (polyQ) disease genes to Parkinsons disease (PD). We compared the distributions of polyQ repeat lengths in 8 common genes (ATXN1, ATXN2, ATXN3, CACNA1A, ATXN7, TBP, ATN1, and HTT) in 299 unrelated patients with autosomal dominant PD (ADPD) and 329 normal controls. We also analyzed the possibility of genetic interactions between ATXN1 and ATXN2, ATXN2 and ATXN3, and ATXN2 and CACNA1A. Intermediate-length polyQ expansions (>24 Qs) of ATXN2 were found in 7 ADPD patients and no controls (7/299 = 2.34% and 0/329 = 0%, respectively; p = 0.0053 < 0.05/8 after Bonferroni correction). These patients showed typical L-DOPA-responsive PD phenotypes. Conversely, no significant differences in polyQ repeat lengths were found between the ADPD patients and the controls for the other 7 genes. Our results may support the hypothesis that ATXN2 polyQ expansion is a specific predisposing factor for multiple neurodegenerative diseases.
Molecular Neurodegeneration | 2017
Maya Ando; Fabienne C. Fiesel; Roman Hudec; Thomas R. Caulfield; Kotaro Ogaki; Paulina Górka-Skoczylas; Dariusz Koziorowski; Andrzej Friedman; Li Chen; Valina L. Dawson; Ted M. Dawson; Guojun Bu; Owen A. Ross; Zbigniew K. Wszolek; Wolfdieter Springer
BackgroundMutations in PINK1 and PARKIN are the most common causes of recessive early-onset Parkinson’s disease (EOPD). Together, the mitochondrial ubiquitin (Ub) kinase PINK1 and the cytosolic E3 Ub ligase PARKIN direct a complex regulated, sequential mitochondrial quality control. Thereby, damaged mitochondria are identified and targeted to degradation in order to prevent their accumulation and eventually cell death. Homozygous or compound heterozygous loss of either gene function disrupts this protective pathway, though at different steps and by distinct mechanisms. While structure and function of PARKIN variants have been well studied, PINK1 mutations remain poorly characterized, in particular under endogenous conditions. A better understanding of the exact molecular pathogenic mechanisms underlying the pathogenicity is crucial for rational drug design in the future.MethodsHere, we characterized the pathogenicity of the PINK1 p.I368N mutation on the clinical and genetic as well as on the structural and functional level in patients’ fibroblasts and in cell-based, biochemical assays.ResultsUnder endogenous conditions, PINK1 p.I368N is expressed, imported, and N-terminally processed in healthy mitochondria similar to PINK1 wild type (WT). Upon mitochondrial damage, however, full-length PINK1 p.I368N is not sufficiently stabilized on the outer mitochondrial membrane (OMM) resulting in loss of mitochondrial quality control. We found that binding of PINK1 p.I368N to the co-chaperone complex HSP90/CDC37 is reduced and stress-induced interaction with TOM40 of the mitochondrial protein import machinery is abolished. Analysis of a structural PINK1 p.I368N model additionally suggested impairments of Ub kinase activity as the ATP-binding pocket was found deformed and the substrate Ub was slightly misaligned within the active site of the kinase. Functional assays confirmed the lack of Ub kinase activity.ConclusionsHere we demonstrated that mutant PINK1 p.I368N can not be stabilized on the OMM upon mitochondrial stress and due to conformational changes in the active site does not exert kinase activity towards Ub. In patients’ fibroblasts, biochemical assays and by structural analyses, we unraveled two pathomechanisms that lead to loss of function upon mutation of p.I368N and highlight potential strategies for future drug development.
Neurology and Clinical Neuroscience | 2015
Ryota Tanaka; Maya Ando; Hideki Shimura; Kazuo Yamashiro; Nobutaka Hattori
Bath‐related headache is a rare headache syndrome that is usually provoked by contact with water, such as during bathing and showering, and mostly affects postmenopausal, middle‐aged or elderly Asian women. The patient was a 59‐year‐old Japanese woman who had experienced repeated intense thunderclap headaches immediately after taking a shower. The trigger episodes for the headache were not only taking a shower, but also tooth brushing and wiping the body with a hot towel. Several medications, including NSAIDs or Ca‐channel blocker, were not effective for the headache; however, pretreatment with zolmitriptan before showering completely attenuated the attack of bath‐related headache. Previous literature showed that bath‐related headache is generally resistant to NSAIDs; and other treatments, such as nimodipine (a Ca2+ channel antagonist), also showed limited effects. As the present case showed the strong effects of triptans for the prevention of bath‐related headache, we discuss its pathophysiology and review the literature.